NCT05839392View on ClinicalTrials.gov

Novel Approaches to Target MECOM/EVI1 in AML

NARecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 13, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
AML, Adult
Interventions
BIOLOGICAL

Biological characterization of AML with MECOM or atypical 3q26 rearrangements

Peripheral blood and bone marrow withdrawal

Trial Locations (1)

Unknown

RECRUITING

Ematologia, Piacenza

All Listed Sponsors
lead

Gruppo Italiano Malattie EMatologiche dell'Adulto

OTHER